ReviewHeart failure clinics2010
Hypertrophic cardiomyopathy.
Review in Heart failure clinics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.Clinical research in cardiology : official journal of the German Cardiac Society · 2018Pooled it
- Mavacamten inhibits myosin activity by stabilizing the myosin interacting-heads motif and stalling motor force generation.Science advances · 2026Article
- Sibjotang Protects against Cardiac Hypertrophy In Vitro and In Vivo.Life (Basel, Switzerland) · 2023Article
- Review
- Genomic findings of hypertrophic and dilated cardiomyopathy characterized in a Thai clinical genetics service.PloS one · 2022Article
- Disease modeling of a mutation in α-actinin 2 guides clinical therapy in hypertrophic cardiomyopathy.EMBO molecular medicine · 2019Article
- Therapeutic potential of AAV9-S15D-RLC gene delivery in humanized MYL2 mouse model of HCM.Journal of molecular medicine (Berlin, Germany) · 2019Article
- Gene therapy strategies in the treatment of hypertrophic cardiomyopathy.Pflugers Archiv : European journal of physiology · 2019Review
- Application of Whole Exome Sequencing in the Clinical Diagnosis and Management of Inherited Cardiovascular Diseases in Adults.Circulation. Cardiovascular genetics · 2017Article
- Novel insights on the relationship between T-tubular defects and contractile dysfunction in a mouse model of hypertrophic cardiomyopathy.Journal of molecular and cellular cardiology · 2016Article
- Constitutive phosphorylation of cardiac myosin regulatory light chain prevents development of hypertrophic cardiomyopathy in mice.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- MicroRNAs Based Therapy of Hypertrophic Cardiomyopathy: The Road Traveled So Far.BioMed research international · 2015Review
- Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies.World journal of cardiology · 2014Review
- Genetics of hypertrophic cardiomyopathy: advances and pitfalls in molecular diagnosis and therapy.The application of clinical genetics · 2014Review
- Remodeling of the heart in hypertrophy in animal models with myosin essential light chain mutations.Frontiers in physiology · 2014Article
- A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management.Circulation. Cardiovascular genetics · 2013Review
- Article
- Effect of hepatocyte growth factor and angiotensin II on rat cardiomyocyte hypertrophy.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2012Article
- Hypertrophic cardiomyopathy: translating cellular cross talk into therapeutics.The Journal of cell biology · 2012Article
- High resolution melting: improvements in the genetic diagnosis of hypertrophic cardiomyopathy in a Portuguese cohort.BMC medical genetics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Important insights into the molecular basis of hypertrophic cardiomyopathy and related diseases have been gained by studying families with inherited cardiac hypertrophy. Integrated clinical and genetic investigations have demonstrated that different genetic defects can give rise to the common phenotype of cardiac hypertrophy. Diverse pathways have been identified, implicating perturbations in force generation, force transmission, intracellular calcium homeostasis, myocardial energetics, and cardiac metabolism in causing disease. Although not fully elucidated, the fundamental mechanisms linking gene mutations to clinical disease are being characterized. Further advances will allow a better understanding of pathogenesis, diagnosis, and treatment, not just of relatively rare inherited cardiomyopathies, but potentially also of relevance to more common acquired forms of hypertrophic remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.